Search

Your search keyword '"Del Mastro, A."' showing total 2,838 results
Start Over Author "Del Mastro, A."
2,838 results on '"Del Mastro, A."'

4. Patterns of care at the end of life: a retrospective study of Italian patients with advanced breast cancer

Author

Giannubilo, Irene, Battistuzzi, Linda, Blondeaux, Eva, Ruelle, Tommaso, Poggio, Francesca Benedetta, Buzzatti, Giulia, D’Alonzo, Alessia, Della Rovere, Federica, Latocca, Maria Maddalena, Molinelli, Chiara, Razeti, Maria Grazia, Nardin, Simone, Arecco, Luca, Perachino, Marta, Favero, Diletta, Borea, Roberto, Pronzato, Paolo, Del Mastro, Lucia, and Bighin, Claudia

Published
2024
Full Text
View/download PDF

6. Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study

Author

Luca Arecco, Maria Maddalena Latocca, Eva Blondeaux, Ferdinando Riccardi, Carmela Mocerino, Valentina Guarneri, Eleonora Mioranza, Giancarlo Bisagni, Elisa Gasparini, Fabio Puglisi, Alexandro Membrino, Antonella Ferro, Vincenzo Adamo, Filippo Giovanardi, Stefano Tamberi, Sara Donati, Elisabetta Landucci, Laura Biganzoli, Sara Piccinini, Simona Pastorino, Evandro de Azambuja, Francesca Poggio, Matteo Lambertini, and Lucia Del Mastro

Subjects
Breast cancer, Premenopausal patients, Adjuvant endocrine therapy, Tamoxifen, Aromatase inhibitors, Ovarian function suppression, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Most premenopausal patients with early breast cancer (eBC) are diagnosed with hormone receptor-positive disease and therefore candidate for adjuvant endocrine therapy (ET). Patients and methods: The Gruppo Italiano Mammella (GIM) 23-POSTER (GIM23) is a multicenter, prospective, observational study conducted in 26 Italian institutions, aiming to evaluate ET choices for premenopausal patients affected by hormone receptor-positive eBC in a real-world setting. Here we report also the results in terms of type of ET prescribed according to the definition of high-risk patients by monarchE and NATALEE trials. Results: Between October 2019 and June 2022, 600 premenopausal patients were included, with a median age of 46 years. Almost half (271, 45.2 %) of the patients had stage I disease, while 254 (42.3 %) and 60 (10.0 %) patients had stage II and III, respectively. Overall, 149 (25.1 %) patients received tamoxifen alone, 83 (14.0 %) tamoxifen with ovarian function suppression (OFS), while 361 (60.9 %) received aromatase inhibitor (AI) with OFS. Patients treated with AI and OFS had higher number of metastatic axillary nodes, higher grade and more often received chemotherapy (all p

Published
2024
Full Text
View/download PDF

7. Patterns of care at the end of life: a retrospective study of Italian patients with advanced breast cancer

Author

Irene Giannubilo, Linda Battistuzzi, Eva Blondeaux, Tommaso Ruelle, Francesca Benedetta Poggio, Giulia Buzzatti, Alessia D’Alonzo, Federica Della Rovere, Maria Maddalena Latocca, Chiara Molinelli, Maria Grazia Razeti, Simone Nardin, Luca Arecco, Marta Perachino, Diletta Favero, Roberto Borea, Paolo Pronzato, Lucia Del Mastro, and Claudia Bighin

Subjects
End of life, Palliative care, Breast cancer, Special situations and conditions, RC952-1245
Abstract

Abstract Objectives To better understand the type of care offered to Italian patients with advanced breast cancer at the End-of-Life (EoL), we conducted a retrospective observational study. EoL was defined as the period of six months before death. Methods One hundred and twenty-one patients with advanced breast cancer (ABC) treated at IRCCS San Martino Policlinic Hospital who died between 2017 and 2021 were included. Data about patient, disease, and treatment characteristics from breast cancer diagnosis to death, along with information about comorbidities, medications, imaging, specialist evaluations, hospitalization, palliative care and home care, hospice admissions, and site of death were collected. Results 98.3% of the patients received at least one line of active treatment at EoL; 52.8% were hospitalized during the selected period. Palliative (13.9%), psychological (7.4%), and nutritional evaluations (8.2%) were underutilized. Palliative home care was provided to 52% of the patients. Most of the patients died at home (66.1%) and fewer than one out of five (18.2%) died at the hospital. Among the patients who died at home, 27.3% had no palliative support. Conclusions Our findings indicate that palliative care in EoL breast cancer patients is still inadequate. Only a minority of patients had psychological and nutritional support While low nutritional support may be explained by the fact that typical symptoms of ABC do not involve the gastrointestinal tract, the lack of psychological support suggests that significant barriers still exist. Data on the site of death are encouraging, indicating that EoL management is increasingly home centered in Italy.

Published
2024
Full Text
View/download PDF

8. De la inexistencia del lenguaje a la narración del «pathos»: Ricœur y Henry en torno a la experiencia literaria

Author

Cesare Aníbal Del Mastro Puccio

Subjects
hermenéutica, fenomenología del lenguaje, fenomenología de la experiencia literaria, Paul Ricoeur, Michel Henry, Romanic languages, PC1-5498, Philology. Linguistics, P1-1091
Abstract

En este artículo, se presentan y se comparan las concepciones del lenguaje que subyacen a la fenomenología de la experiencia literaria de Paul Ricœur y Michel Henry. Por un lado, mientras que la teoría de la recepción de Ricœur responde a la noción de correferencia que vincula el lenguaje con el mundo, Henry se concentra en el acto de creación basado en el proceso de coimpresión, en virtud del cual una palabra es vista y simultáneamente resuena de modo invisible en el escritor según determinadas tonalidades afectivas. Por otro lado, si el núcleo de la hermenéutica ricœuriana radica en que el seguimiento de la intriga narrativa configura la identidad del lector y relanza su acción en el mundo, la fenomenología henriana de la vida sostiene que toda comprensión de uno mismo y toda relación con el otro están precedidas por la equivalencia más radical entre narración, pathos del sufrimiento y pathos del gozo. Este recorrido conceptual tiene como objetivo proponer, en la conclusión del artículo, una «hermenéutica de la vida» en cuanto marco teórico para el análisis de textos literarios cuyas figuras del afecto y de la fuerza vitales superan el modelo tradicional de la representación.

Published
2024

9. 'Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper'

Author

Pierfranco Conte, Eva Ciruelos, Giuseppe Curigliano, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Gennari, Antonio Llombart, Miguel Martìn, Francesca Poggio, Aleix Prat, Fabio Puglisi, and Cristina Saura

Subjects
Breast cancer, HER2, Tucatinib, TKI, Brain metastases, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Introduction: Advancements in monoclonal antibodies, tyrosine kinase inhibitors, and antibody drug conjugates (ADCs) have notably enhanced outcomes for metastatic HER2-positive breast cancer patients. Despite the expanding treatment options and clinical complexities, determining the optimal sequence of HER2-targeted therapies remains partly uncertain, influenced by various factors. Methods: To refine HER2-positive metastatic breast cancer management, particularly regarding tucatinib's position, a Steering Committee of leading oncologists in breast cancer care devised a panel of statements via a Delphi approach, focusing on five key topics: general clinical management, therapeutic approaches for patients with HER2-positive breast cancer and brain metastases, treatment sequence, and tucatinib's safety and efficacy. Results: A total of 29 statements were deliberated, with strong consensus achieved for most. However, no consensus emerged regarding the management of brain progression alongside stable extracranial disease: 48 % advocated for switching to tucatinib, while 53 % favored a stereotactic brain radiotherapy (SBRT) approach if feasible. Conclusion: The unanimous consensus attained in this Delphi panel, particularly regarding tucatinib's efficacy and safety, underscores oncologists' recognition of its clinical significance based on existing trial data. These findings align closely with current literature, shedding light on areas necessitating further investigation, not thoroughly explored in prior studies. Moreover, the results underscore the scarcity of data on managing brain progression alongside stable extracranial disease, emphasizing the imperative for dedicated research to address these gaps and yield definitive insights.

Published
2024
Full Text
View/download PDF

10. The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Author

Molinelli, Chiara, Bruzzone, Marco, Blondeaux, Eva, Ruelle, Tommaso, Lanzavecchia, Chiara, De Laurentiis, Michelino, Russo, Stefania, Riccardi, Ferdinando, Sini, Valentina, Cognetti, Francesco, Arpino, Grazia, Fabi, Alessandra, Pugliese, Palma, Collovà, Elena, Fontana, Andrea, Puglisi, Fabio, Bighin, Claudia, Lambertini, Matteo, and Del Mastro, Lucia

Published
2024
Full Text
View/download PDF

11. Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review

Author

Zambelli, Alberto, Cortesi, Laura, Gaudio, Mariangela, Arpino, Grazia, Bianchini, Giampaolo, Caruso, Francesco, Cinieri, Saverio, Curigliano, Giuseppe, Del Mastro, Lucia, De Placido, Sabino, Fabi, Alessandra, Fortunato, Lucio, Generali, Daniele, Gennari, Alessandra, Gori, Stefania, Grandi, Giovanni, Guarneri, Valentina, Klinger, Marco, Livi, Lorenzo, Marchiò, Caterina, Palumbo, Isabella, Panizza, Pietro, Pravettoni, Gabriella, Pruneri, Giancarlo, Puglisi, Fabio, Sapino, Anna, Tinterri, Corrado, Turchetti, Daniela, and De Laurentiis, Michelino

Published
2024
Full Text
View/download PDF

12. Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study

Author

Arecco, Luca, Latocca, Maria Maddalena, Blondeaux, Eva, Riccardi, Ferdinando, Mocerino, Carmela, Guarneri, Valentina, Mioranza, Eleonora, Bisagni, Giancarlo, Gasparini, Elisa, Puglisi, Fabio, Membrino, Alexandro, Ferro, Antonella, Adamo, Vincenzo, Giovanardi, Filippo, Tamberi, Stefano, Donati, Sara, Landucci, Elisabetta, Biganzoli, Laura, Piccinini, Sara, Pastorino, Simona, de Azambuja, Evandro, Poggio, Francesca, Lambertini, Matteo, and Del Mastro, Lucia

Published
2024
Full Text
View/download PDF

17. Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial

Author

Poggio, F., Blondeaux, E., Tagliamento, M., Perachino, M., Nardin, S., Conte, B., Giuliano, M., Arpino, G., De Laurentiis, M., Gravina, A., Bisagni, G., Rimanti, A., Turletti, A., Nisticò, C., Magnolfi, E., Gasparro, S., Fabi, A., Garrone, O., Alicicco, M.G., Urracci, Y., Poletti, P., Correale, P., Molinelli, C., Fozza, A., Puglisi, F., Colantuoni, G., Fregatti, P., Boni, L., Lambertini, M., and Del Mastro, L.

Published
2024
Full Text
View/download PDF

19. Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients

Author

Federica Miglietta, Letizia Pontolillo, Carmine De Angelis, Roberta Caputo, Monica Marino, Emilio Bria, Rossana Di Rienzo, Annarita Verrazzo, Carlo Buonerba, Giampaolo Tortora, Giuseppe Di Lorenzo, Lucia Del Mastro, Mario Giuliano, Filippo Montemurro, Fabio Puglisi, Valentina Guarneri, Michelino De Laurentiis, Luca Scafuri, and Grazia Arpino

Subjects
Breast cancer, Gender minorities, Male, Transgender and gender diverse people, Gender diversity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: The last years have seen unprecedented improvement in breast cancer (BC) survival rates. However, this entirely apply to female BC patients, since gender minorities (male, transgender/gender-diverse) are neglected in BC phase III registration clinical trials. Methods: We conducted a scoping review of phase III clinical trials of agents with a current positioning within the therapeutic algorithms of BC. Results: We selected 51 phase III trials. Men enrollment was allowed in 35.3% of trials. In none of the trial inclusion/exclusion criteria referred to transgender/gender-diverse people. A numerical higher rate of enrolled men was observed in the contemporary as compared to historical group.We found a statistically significant association between the drug class and the possibility of including men: 100%, 80%, 50%, 33.3%, 25%, 10% and 9.1% of trials testing ICI/PARP-i, ADCs, PI3K/AKT/mTOR-i, anti-HER2 therapy, CDK4/6-i, ET alone, and CT alone.Overall, 77409 patients were enrolled, including 112 men (0.2%). None of the trial reported transgender/gender-diverse people proportion. Studies investigating PARP-i were significantly associated with the highest rate of enrolled men (1.42%), while the lowest rates were observed for trials of CT (0.13%), ET alone (0.10%), and CDK 4/6-I (0.08%), p

Published
2024
Full Text
View/download PDF

20. Spatial predictors of immunotherapy response in triple-negative breast cancer

Author

Wang, Xiao Qian, Danenberg, Esther, Huang, Chiun-Sheng, Egle, Daniel, Callari, Maurizio, Bermejo, Begoña, Dugo, Matteo, Zamagni, Claudio, Thill, Marc, Anton, Anton, Zambelli, Stefania, Russo, Stefania, Ciruelos, Eva Maria, Greil, Richard, Győrffy, Balázs, Semiglazov, Vladimir, Colleoni, Marco, Kelly, Catherine M., Mariani, Gabriella, Del Mastro, Lucia, Biasi, Olivia, Seitz, Robert S., Valagussa, Pinuccia, Viale, Giuseppe, Gianni, Luca, Bianchini, Giampaolo, and Ali, H. Raza

Published
2023
Full Text
View/download PDF

21. Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients

Author

Miglietta, Federica, Pontolillo, Letizia, De Angelis, Carmine, Caputo, Roberta, Marino, Monica, Bria, Emilio, Di Rienzo, Rossana, Verrazzo, Annarita, Buonerba, Carlo, Tortora, Giampaolo, Di Lorenzo, Giuseppe, Del Mastro, Lucia, Giuliano, Mario, Montemurro, Filippo, Puglisi, Fabio, Guarneri, Valentina, De Laurentiis, Michelino, Scafuri, Luca, and Arpino, Grazia

Published
2024
Full Text
View/download PDF

22. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

Author

Kaidar-Person, Orit, Meattini, Icro, Boersma, Liesbeth J., Becherini, Carlotta, Cortes, Javier, Curigliano, Giuseppe, de Azambuja, Evandro, Harbeck, Nadia, Rugo, Hope S., Del Mastro, Lucia, Gennari, Alessandra, Isacke, Clare M., Vestmø Maraldo, Maja, Marangoni, Elisabetta, Nader Marta, Gustavo, Mjaaland, Ingvil, Salvestrini, Viola, Spanic, Tanja, Visani, Luca, Morandi, Andrea, Lambertini, Matteo, Livi, Lorenzo, Coles, Charlotte E., Poortmans, Philip, and Offersen, Birgitte V.

Published
2024
Full Text
View/download PDF

23. Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials

Author

Blondeaux, Eva, Xie, Wanling, Carmisciano, Luca, Mura, Silvia, Sanna, Valeria, De Laurentiis, Michelino, Caputo, Roberta, Turletti, Anna, Durando, Antonio, De Placido, Sabino, De Angelis, Carmine, Bisagni, Giancarlo, Gasparini, Elisa, Rimanti, Anita, Puglisi, Fabio, Mansutti, Mauro, Landucci, Elisabetta, Fabi, Alessandra, Arecco, Luca, Perachino, Marta, Bruzzone, Marco, Boni, Luca, Lambertini, Matteo, Del Mastro, Lucia, and Regan, Meredith M.

Published
2024
Full Text
View/download PDF

25. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

Author

Alkner, Sara, Bhattacharya, Indrani S., Boersma, Liesbeth, Callari, Maurizio, Clarke, Robert B., Del Mastro, Lucia, Ekholm, Maria, Gennari, Alessandra, Kirby, Anna M., Kroeze, Stephanie, Malumbres, Marcos, Vestmø Maraldo, Maja, Marta, Gustavo Nader, Mjaaland, Ingvil, Morgan, Gilberto, Pistilli, Barbara, Paluch-Shimon, Shani, Rivera, Sofia, Rottenberg, Sven, Saura, Cristina, Skyttä, Tanja, Spanic, Tanja, Meattini, Icro, Becherini, Carlotta, Caini, Saverio, Coles, Charlotte E, Cortes, Javier, Curigliano, Giuseppe, de Azambuja, Evandro, Isacke, Clare M, Harbeck, Nadia, Kaidar-Person, Orit, Marangoni, Elisabetta, Offersen, Birgitte V, Rugo, Hope S, Salvestrini, Viola, Visani, Luca, Morandi, Andrea, Lambertini, Matteo, Poortmans, Philip, and Livi, Lorenzo

Published
2024
Full Text
View/download PDF

26. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Author

Loibl, S., André, F., Bachelot, T., Barrios, C.H., Bergh, J., Burstein, H.J., Cardoso, M.J., Carey, L.A., Dawood, S., Del Mastro, L., Denkert, C., Fallenberg, E.M., Francis, P.A., Gamal-Eldin, H., Gelmon, K., Geyer, C.E., Gnant, M., Guarneri, V., Gupta, S., Kim, S.B., Krug, D., Martin, M., Meattini, I., Morrow, M., Janni, W., Paluch-Shimon, S., Partridge, A., Poortmans, P., Pusztai, L., Regan, M.M., Sparano, J., Spanic, T., Swain, S., Tjulandin, S., Toi, M., Trapani, D., Tutt, A., Xu, B., Curigliano, G., and Harbeck, N.

Published
2024
Full Text
View/download PDF

28. Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients

Author

Parisi, Francesca, De Luca, Giuseppa, Mosconi, Manuela, Lastraioli, Sonia, Dellepiane, Chiara, Rossi, Giovanni, Puglisi, Silvia, Bennicelli, Elisa, Barletta, Giulia, Zullo, Lodovica, Santamaria, Sara, Mora, Marco, Ballestrero, Alberto, Montecucco, Fabrizio, Bellodi, Andrea, Del Mastro, Lucia, Lambertini, Matteo, Barisione, Emanuela, Cittadini, Giuseppe, Tagliabue, Elena, Spagnolo, Francesco, Tagliamento, Marco, Coco, Simona, Dono, Mariella, and Genova, Carlo

Published
2024
Full Text
View/download PDF

29. Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients

Author

Francesca Parisi, Giuseppa De Luca, Manuela Mosconi, Sonia Lastraioli, Chiara Dellepiane, Giovanni Rossi, Silvia Puglisi, Elisa Bennicelli, Giulia Barletta, Lodovica Zullo, Sara Santamaria, Marco Mora, Alberto Ballestrero, Fabrizio Montecucco, Andrea Bellodi, Lucia Del Mastro, Matteo Lambertini, Emanuela Barisione, Giuseppe Cittadini, Elena Tagliabue, Francesco Spagnolo, Marco Tagliamento, Simona Coco, Mariella Dono, and Carlo Genova

Subjects
Lung cancer, Liquid biopsy, EGFR, Targeted therapy, Emergency department, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Molecular characterization is pivotal for managing non-small cell lung cancer (NSCLC), although this process is often time-consuming and patients’ conditions might worsen while molecular analyses are processed.Our primary aim was to evaluate the performance of “up-front” next-generation sequencing (NGS) through liquid biopsy (LB) of hospitalized patients with newly detected lung neoplasm in parallel with conventional diagnosis. The secondary aim included longitudinal monitoring through LB of patients with oncogenic alterations at baseline. Methods: We enrolled 47 consecutive patients immediately after hospitalization and radiological detection of symptomatic lung neoplasm. LB from peripheral blood was performed at baseline, in parallel with conventional biopsy (CB), when feasible. Additionally, LBs were repeated during treatment in patients with actionable gene alterations at baseline. Oncomine™ Lung cfTNA Research Assay panel was employed for processing plasma samples in NGS. Results: 47 hospitalized patients were enrolled. LB identified 28 patients with gene alterations, including mutations of EGFR (n = 7), KRAS (n = 12), ERBB2 (n = 1), TP53 (n = 2), BRAF (n = 1), one ALK rearrangement, and 4 patients with combined mutations involving EGFR, KRAS and PIK3CA.LB and CB were consistent, except for two patients. Three patients with positive LB for oncogenic drivers did not undergo CB due to contraindications.Median time to molecular results after LB was significantly lower compared to time to molecular report after CB (11 versus 22 days, p < 0.001). Conclusions: Despite limited numbers, our study supports the role of front-line LB for improving management of symptomatic patients with lung cancer, potentially leading to early targeted therapy initiation.

Published
2024
Full Text
View/download PDF

30. Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer

Author

Luca Licata, Giulia Viale, Mario Giuliano, Giuseppe Curigliano, Mariana Chavez-MacGregor, Julia Foldi, Oluchi Oke, Joseph Collins, Lucia Del Mastro, Fabio Puglisi, Filippo Montemurro, Claudio Vernieri, Lorenzo Gerratana, Sara Giordano, Alessia Rognone, Lorenzo Sica, Oreste Davide Gentilini, Stefano Cascinu, Lajos Pusztai, Antonio Giordano, Carmen Criscitiello, and Giampaolo Bianchini

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Adjuvant chemotherapy recommendations for ER+/HER2− early-stage breast cancers (eBC) involve integrating prognostic and predictive information which rely on physician judgment; this can lead to discordant recommendations. In this study we aim to evaluate whether Oncotype DX improves confidence and agreement among oncologists in adjuvant chemotherapy recommendations. We randomly select 30 patients with ER+/HER2− eBC and recurrence score (RS) available from an institutional database. We ask 16 breast oncologists with varying years of clinical practice in Italy and the US to provide recommendation for the addition of chemotherapy to endocrine therapy and their degree of confidence in the recommendation twice; first, based on clinicopathologic features only (pre-RS), and then with RS result (post-RS). Pre-RS, the average rate of chemotherapy recommendation is 50.8% and is higher among junior (62% vs 44%; p

Published
2023
Full Text
View/download PDF

32. Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients

Author

Arenare, L., Porta, C., Barberio, D., Terzolo, S., Zagonel, V., Pisconti, S., Del Mastro, L., Pinto, C., Bilancia, D., Cinieri, S., Rizzo, M., Migliaccio, G., Montesarchio, V., Del Campo, L., De Lorenzo, F., Iannelli, E., Traclò, F., Gitto, L., Vaccaro, M.C., Frontini, L., Giannarelli, D., Bryce, J., Piccirillo, M.C., Jommi, C., Efficace, F., Riva, S., Di Maio, M., Gallo, C., and Perrone, F.

Published
2023
Full Text
View/download PDF

33. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis

Author

Arecco, L., Blondeaux, E., Bruzzone, M., Latocca, M.M., Mariamidze, E., Begijanashvili, S., Sokolovic, E., Gentile, G., Scavone, G., Ottonello, S., Boutros, A., Vaz-Luis, I., Saura, C., Anderson, R.A., Demeestere, I., Azim, H.A., Jr, de Azambuja, E., Peccatori, F.A., Del Mastro, L., Partridge, A.H., and Lambertini, M.

Published
2023
Full Text
View/download PDF

36. Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials

Author

Taylor, Carolyn, Dodwell, David, McGale, Paul, Hills, Robert K, Berry, Richard, Bradley, Rosie, Braybrooke, Jeremy, Clarke, Mike, Gray, Richard, Holt, Francesca, Liu, Zulian, Pan, Hongchao, Peto, Richard, Straiton, Ewan, Coles, Charlotte, Duane, Fran, Hennequin, Christophe, Jones, Glenn, Kühn, Thorsten, Oliveros, Sileida, Overgaard, Jens, Pritchard, Kathy I, Suh, Chang-Ok, Beake, Graham, Boddington, Clare, Davies, Christina, Davies, Lucy, Evans, Vaughan, Gay, Jo, Gettins, Lucy, Godwin, Jon, James, Sam, Kerr, Amanda, Liu, Hui, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Nakahara, Mariko, Read, Simon, Taylor, Hannah, Ferguson, John, Scheurlen, Hans, Zurrida, Stefano, Galimberti, Viviana, Ingle, James, Valagussa, Pinuccia, Veronesi, Umberto, Anderson, Stewart, Tang, Gong, Fisher, Bernard, Fossa, Sophie, Valborg Reinertsen, Kristin, Host, Herman, Muss, Hyman, Holli, Kaija, Albain, Kathy, Arriagada, Rodrigo, Bartlett, John, Bergsten-Nordström, Elizabeth, Bliss, Judith, Brain, Etienne, Carey, Lisa, Coleman, Robert, Cuzick, Jack, Davidson, Nancy, Del Mastro, Lucia, Di Leo, Angelo, Dignam, James, Dowsett, Mitch, Ejlertsen, Bent, Francis, Prue, García-Sáenz, José Angel, Gelber, Rich, Gnant, Michael, Goetz, Matthew, Goodwin, Pam, Halpin-Murphy, Pat, Hayes, Dan, Hill, Catherine, Jagsi, Reshma, Janni, Wolfgang, Loibl, Sibylle, Mamounas, Eleftherios, Martín, Miguel, McIntosh, Stuart, Mukai, Hirofumi, Nekljudova, Valentina, Norton, Larry, Ohashi, Yasuo, Piccart, Martine, Pierce, Lori, Raina, Vinod, Rea, Daniel, Regan, Meredith, Robertson, John, Rutgers, Emiel, Salgado, Roberto, Slamon, Dennis, Spanic, Tanja, Sparano, Joseph, Steger, Guenther, Toi, Masakazu, Tutt, Andrew, Viale, Giuseppe, Wang, Xiang, Wilcken, Nicholas, Wolmark, Norman, Yu, Ke-Da, Cameron, David, Bergh, Jonas, Swain, Sandra, Whelan, Tim, and Poortmans, Philip

Published
2023
Full Text
View/download PDF

37. Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center

Author

Vallome, Giacomo, Cafaro, Iacopo, Bottini, Annarita, Dellepiane, Chiara, Rossi, Giovanni, Bennicelli, Elisa, Parisi, Francesca, Zullo, Lodovica, Tagliamento, Marco, Ballestrero, Alberto, Barisione, Emanuela, Grazia Piroddi, Ines Maria, Montecucco, Fabrizio, Carbone, Federico, Pronzato, Paolo, Lambertini, Matteo, Spagnolo, Francesco, Barletta, Giulia, Barcellini, Lucrezia, Ferrante, Michele, Nardin, Simone, Coco, Simona, Marconi, Silvia, Zinoli, Linda, Moscatelli, Paolo, Arboscello, Eleonora, Del Mastro, Lucia, Bellodi, Andrea, and Genova, Carlo

Published
2023
Full Text
View/download PDF

39. Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread

Author

Criscitiello, Carmen, Corti, Chiara, De Laurentiis, Michelino, Bianchini, Giampaolo, Pistilli, Barbara, Cinieri, Saverio, Castellan, Lucio, Arpino, Grazia, Conte, Pierfranco, Di Meco, Francesco, Gennari, Alessandra, Guarneri, Valentina, Visani, Luca, Livi, Lorenzo, Marchetti, Paolo, Puglisi, Fabio, Viale, Giuseppe, Del Mastro, Lucia, De Placido, Sabino, and Curigliano, Giuseppe

Published
2023
Full Text
View/download PDF

40. Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study

Author

Massimo Di Maio, Claudia Bighin, Francesco Schettini, Tommaso Ruelle, Laura Marandino, Alessandra Fabi, Carmine De Angelis, Mario Giuliano, Pietro De Placido, Michelino De Laurentiis, Ferdinando Riccardi, Caterina Picotto, Fabio Puglisi, Lucia Del Mastro, and Grazia Arpino

Subjects
Breast cancer, HER2-Positive, Metastasis, First line of therapy, Trastuzumab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Treatment for HER2-positive (+) metastatic breast cancer has improved in the last decade. We analyzed treatment changes over time and their impact on patients outcomes in a real-world dataset. Methods: Data from 637 HER2+ patients with metastatic breast cancer enrolled in the multicenter Italian GIM14/BIOMETA study were retrieved. Progression-free survival (PFS) over time was evaluated according to the type of anti-HER2 therapy, disease onset (de novo vs. relapsing), metastatic site, and year of treatment (2000–2013 vs. 2014–2020). Results: Median follow-up was 64.4 months. Overall, for first-line therapies, mPFS was 16.5 vs 19.5 months for patients treated in 2000–2013 vs 2014–2020 (HR: 0.78, 95% CI:0.65–0.94, P = 0.008). mPFS improved over time in all patients except for those with brain metastasis. Interestingly mPFS was 17.4 vs13.4 months (HR, 1.49; 95% CI, 1.13–1.98, P = 0.005) in 2000–2013 and 24.4 vs 20.9 months (HR 1.04; 95% CI 0.78–1.40 p = 0.77) in 2014–2020 in pts without vs with liver metastases. For second line therapies, the overall median PFS was 9.6 months (95% CI, 8.31–10.97) and did not change over time. Conclusion: Median first-line PFS improved since 2014, mainly due to the introduction of pertuzumab. The outcome of patients with liver metastases appears to have improved in recent years. Patients with brain metastases had the worst PFS, which also did not improve over time.

Published
2023
Full Text
View/download PDF

41. Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center

Author

Giacomo Vallome, Iacopo Cafaro, Annarita Bottini, Chiara Dellepiane, Giovanni Rossi, Elisa Bennicelli, Francesca Parisi, Lodovica Zullo, Marco Tagliamento, Alberto Ballestrero, Emanuela Barisione, Ines Maria Grazia Piroddi, Fabrizio Montecucco, Federico Carbone, Paolo Pronzato, Matteo Lambertini, Francesco Spagnolo, Giulia Barletta, Lucrezia Barcellini, Michele Ferrante, Simone Nardin, Simona Coco, Silvia Marconi, Linda Zinoli, Paolo Moscatelli, Eleonora Arboscello, Lucia Del Mastro, Andrea Bellodi, and Carlo Genova

Subjects
Lung cancer, Cancer diagnosis, Performance status, Molecular characterization, Emergency department, Science (General), Q1-390, Social sciences (General), H1-99
Abstract

Background: Lung cancer patients diagnosed following emergency admission often present with advanced disease and poor performance status, leading to suboptimal treatment options and outcomes. This study aimed to investigate the clinical and molecular characteristics, treatment initiation, and survival outcomes of these patients. Methods: We retrospectively analyzed data from 124 patients diagnosed with lung cancer following emergency admission at a single institution. Clinical characteristics, results of molecular analyses for therapeutic purpose, systemic treatment initiation, and survival outcomes were assessed. Correlations between patients’ characteristics and treatment initiation were analyzed. Results: Median age at admission was 73 years, and 79.0 % had at least one comorbidity. Most patients (87.1 %) were admitted due to cancer-related symptoms. Molecular analyses were performed in 89.5 % of advanced non-small cell lung cancer (NSCLC) cases. In this subgroup, two-thirds (66.2 %) received first-line therapy. Median overall survival (OS) was 3.9 months for the entire cohort, and 2.9 months for patients with metastatic lung cancer. Among patients with advanced NSCLC, OS was significantly longer for those with actionable oncogenic drivers and those who received first-line therapy. Improvement of performance status during hospitalization resulted in increased probability of receiving first-line systemic therapy. Discussion: Patients diagnosed with lung cancer following emergency admission demonstrated poor survival outcomes. Treatment initiation, particularly for patients with actionable oncogenic drivers, was associated with longer OS. These findings highlight the need for proactive medical approaches, including improving access to molecular diagnostics and targeted treatments, to optimize outcomes in this patient population.

Published
2023
Full Text
View/download PDF

42. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

Author

Valenza, Carmine, Trapani, Dario, Gandini, Sara, Sposetti, Caterina, Boscolo Bielo, Luca, Marra, Antonio, Giarratano, Tommaso, Favero, Diletta, Cortesi, Laura, Moscetti, Luca, Pistelli, Mirco, Berardi, Rossana, Zambelli, Alberto, Lambertini, Matteo, Del Mastro, Lucia, Guarneri, Valentina, Vernieri, Claudio, and Curigliano, Giuseppe

Published
2023
Full Text
View/download PDF

46. Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial

Author

Malorni, Luca, Bianchini, Giampaolo, Caputo, Roberta, Zambelli, Alberto, Puglisi, Fabio, Bianchi, Giulia V., Del Mastro, Lucia, Paris, Ida, Montemurro, Filippo, Allegrini, Giacomo, Colleoni, Marco, Tamberi, Stefano, Zamagni, Claudio, Cazzaniga, Marina E., Orditura, Michele, Guarneri, Valentina, Castelletti, Daniela, Benelli, Matteo, Di Marino, Mariacristina, Arpino, Grazia, and De Laurentiis, Michelino

Published
2023
Full Text
View/download PDF

47. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

Author

Lambertini, Matteo, Blondeaux, Eva, Bisagni, Giancarlo, Mura, Silvia, De Placido, Sabino, De Laurentiis, Michelino, Fabi, Alessandra, Rimanti, Anita, Michelotti, Andrea, Mansutti, Mauro, Russo, Antonio, Montemurro, Filippo, Frassoldati, Antonio, Durando, Antonio, Gori, Stefania, Turletti, Anna, Tamberi, Stefano, Urracci, Ylenia, Fregatti, Piero, Razeti, Maria Grazia, Caputo, Roberta, De Angelis, Carmine, Sanna, Valeria, Gasparini, Elisa, Agostinetto, Elisa, de Azambuja, Evandro, Poggio, Francesca, Boni, Luca, and Del Mastro, Lucia

Published
2023
Full Text
View/download PDF

49. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study

Author

Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A, Kim, H, Di Meglio, A, Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, H, Phillips, K, Toss, A, Rousset-Jablonski, C, Peccatori, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, M, Rodriguez-Wallberg, K, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y, Maria, C, Azim, H, Boni, L, Partridge, A, Lambertini M., Blondeaux E., Agostinetto E., Hamy A. -S., Kim H. J., Di Meglio A., Molho R. B., Hilbers F., Pogoda K., Carrasco E., Punie K., Bajpai J., Ignatiadis M., Moore H. C. F., Phillips K. -A., Toss A., Rousset-Jablonski C., Peccatori F. A., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Ruddy K. J., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Del Mastro L., Puglisi F., Estevez-Diz M. D. P., Rodriguez-Wallberg K. A., Mrinakova B., Meister S., Livraghi L., Clatot F., Yerushalmi R., De Angelis C., Sanchez-Bayona R., Meattini I., Cichowska-Cwalinska N., Berliere M., Salama M., De Giorgi U., Sonnenblick A., Chiodi C., Lee Y. -J., Maria C., Azim H. A., Boni L., Partridge A. H., Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A, Kim, H, Di Meglio, A, Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, H, Phillips, K, Toss, A, Rousset-Jablonski, C, Peccatori, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, M, Rodriguez-Wallberg, K, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y, Maria, C, Azim, H, Boni, L, Partridge, A, Lambertini M., Blondeaux E., Agostinetto E., Hamy A. -S., Kim H. J., Di Meglio A., Molho R. B., Hilbers F., Pogoda K., Carrasco E., Punie K., Bajpai J., Ignatiadis M., Moore H. C. F., Phillips K. -A., Toss A., Rousset-Jablonski C., Peccatori F. A., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Ruddy K. J., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Del Mastro L., Puglisi F., Estevez-Diz M. D. P., Rodriguez-Wallberg K. A., Mrinakova B., Meister S., Livraghi L., Clatot F., Yerushalmi R., De Angelis C., Sanchez-Bayona R., Meattini I., Cichowska-Cwalinska N., Berliere M., Salama M., De Giorgi U., Sonnenblick A., Chiodi C., Lee Y. -J., Maria C., Azim H. A., Boni L., and Partridge A. H.

Abstract

(Abstracted from JAMA 2024;331(1):49-59 Individuals who are diagnosed with breast cancer at a young age are often carriers of a pathogenic variant in the BRCA1 or BRCA2 genes, and many young women in this situation are interested in preserving future fertility, if possible. Reproductive counseling in this situation can be complex due to the risk of passing on the variant, as well as the implications on their own fertility, as the mutation can impact ovarian reserve, fertility potential, and other factors.

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results